Advertisement.

IBRX Projected Dividend Yield

ImmunityBio Inc ( NASDAQ : IBRX )

ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to enhance the immune system against cancers and infectious diseases. It uses proprietary platforms to activate both the innate and adaptive immune systems, targeting cancer and pathogens. These platforms include antibody-cytokine fusion proteins, DNA, RNA, and recombinant protein vaccines, and cell therapies. Its lead product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein designed to boost immune response. ImmunityBio aims to orchestrate a comprehensive immune attack on cancer and infectious diseases through its innovative therapies.

21 YEAR PERFORMANCE RESULTS

IBRX Dividend History Detail
IBRX Dividend News
IBRX Competitors News

# of Shares: 0

Closing Price: 2.47

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000